A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care

Nordic Journal of Psychiatry

Volumn 61, Issue 2, 2007, Pages 100-108

  Sørensen, Jan ^a   Stage, Kurt ^b   Damsbo, Niels ^a   Lay, Agathe Le ^c   Hemels, Michiel ^c  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c Lundbeck   (France)

Author keywords

Citalopram; Cost effectiveness; Denmark; Escitalopram; Major depressive disorder; Venlafaxine

Indexed keywords

CITALOPRAM; ESCITALOPRAM; GENERIC DRUG; LITHIUM; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DENMARK; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG SUBSTITUTION; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH SURVEY; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MEDICAL EXPERT; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTIVARIATE ANALYSIS; OUTPATIENT DEPARTMENT; PATIENT REFERRAL; PRIMARY MEDICAL CARE; PROBABILITY; PRODUCTIVITY; REMISSION; SCORING SYSTEM; STATISTICAL ANALYSIS; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; COST-BENEFIT ANALYSIS; CYCLOHEXANOLS; DECISION SUPPORT TECHNIQUES; DENMARK; DEPRESSIVE DISORDER, MAJOR; DRUG COSTS; HUMANS; MODELS, ECONOMIC; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; REMISSION INDUCTION;

EID: 34247142832     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.1080/08039480701226070     Document Type: Article

References (56)

1. Angst, J., Amrein, R. and Stabl, M. (1995) Moclobemide and tricyclic antidepressants in severe depression: Meta-analysis and prospective studies. J Clin Psychopharmacol, 15:4, pp. 16S-23S.
2. Olsen, LR, Mortensen, EL and Bech, P. (2004) Prevalence of major depression and stress indicators in the Danish general population. Acta Psychiatr Scand, 109, pp. 96-103.
3. Hildebrandt, MG, Stage, KB and Kragh-Soerensen, P. (2003) Gender differences in severity, symptomatology and distribution of melancholia in major depression. Psychopathology, 36, pp. 204-212.
4. Stage, KB, Casier, P. and Trosko, O. (2004) [Depression]. Ugeskr Laeger, 166, pp. 1311-1313.
5. (2005) [Consumption of antidepressiva in Denmark in the primary health care sector during 1994-2003].
6. (2005) [New rules for substitution on drugs].
7. (2000)
8. (2001)
9. (2004)
10. Stage, KB. (2003) Depression management guidelines.
11. Demyttenaere, K., Hemels, ME, Hudry, J. and Annemans, L. (2005) A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin Ther, 27, pp. 111-124.
12. Francois, C., Toumi, M., Aakhus, AM and Hansen, K. (2003) A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway. Eur J Health Econ, 4, pp. 12-19.
13. Sullivan, PW, Valuck, R., Saseen, J. and MacFall, HM. (2004) A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs, 18, pp. 911-932.
14. Trivedi, MH, Wan, GJ, Mallick, R., Chen, J., Casciano, R. and Geissler, EC (2004) Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder. J Clin Psychopharmacol, 24, pp. 497-506.
15. Hemels, ME, Kasper, S., Walter, E. and Einarson, TR. (2004) Cost-effectiveness analysis of escitalopram: A new SSRI in the first-line treatment of major depressive disorder in Austria. Curr Med Res Opin, 20, pp. 869-878.
16. Hemels, ME, Kasper, S., Walter, E. and Einarson, TR. (2004) Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression. Ann Pharmacother, 38, pp. 954-960.
17. Lenox-Smith, A., Conway, P. and Knight, C. (2004) Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK. Pharmacoeconomics, 22, pp. 311-319.
18. Casciano, R. (2003) A pharmacoeconomic evaluation of major depressive disorder. Manag Care Interface, pp. 16-21.
19. Doyle, JJ, Casciano, J., Arikian, S., Tarride, JE, Gonzalez, MA and Casciano, R. (2001) A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): A comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. Value Health, 4, pp. 16-31.
20. Freeman, H., Arikian, S. and Lenox-Smith, A. (2000) Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom. Pharmacoeconomics, 18, pp. 143-148.
21. Einarson, TR, Addis, A. and Iskedjian, M. (1997) Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder. Pharmacoeconomics, 12, pp. 286-296.
22. Einarson, TR, Arikian, S., Sweeney, S. and Doyle, J. (1995) A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders. Clin Ther, 17, pp. 136-153.
23. Einarson, TR. (2004) Evidence based review of escitalopram in treating major depressive disorder in primary care. Int Clin Psychopharmacol, 19, pp. 305-310.
24. Nuijten, MJ, Hardens, M. and Souetre, E. (1995) A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression. Pharmacoeconomics, 8, pp. 159-168.
25. Fernandez, JL, Montgomery, S. and Francois, C. (2005) Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics, 23, pp. 155-167.
26. Entsuah, R. and Chitra, R. (1997) A benefit-risk analysis of once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Psychopharmacol Bull, 33, pp. 671-676.
27. Morrow, TJ. (2001) The pharmacoeconomics of venlafaxine in depression. Am J Manag Care, 7, pp. S386-S392.
28. Sclar, DA, Skaer, TL, Robison, LM and Galin, RS. (1999) Economic appraisal of citalopram in the management of single-episode depression. J Clin Psychopharmacol, 19, pp. 47S-54S.
29. François, C., Sintonen, H. and Toumi, M. (2002) Introduction of escitalopram, a new SSRI in Finland: Comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of the budgetary impact. J Med Econ, 5, pp. 91-107.
30. Lepola, UM, Wade, A. and Andersen, HF. (2004) Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol, 19, pp. 149-155.
31. Drummond, M. and Pang, F. (2001) Transferability of economic evaluation results. Economic evaluation in health care, pp. 256-276. Oxford University Press, Oxford
32. Gold, MR, Siegel, JE, Rusell, LB and Weinstein, MC. (1996) Cost-effectiveness in health and medicine, Oxford University Press
33. Montgomery, SA and Asberg, M. (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry, 134, pp. 382-389.
34. Korner, A., Nielsen, BM, Eschen, F., Moller-Madsen, S., Stender, A. and Christensen, EM (1990) Quantifying depressive symptomatology: Inter-rater reliability and inter-item correlations. J Affect Disord, 20, pp. 143-149.
35. Olver, JS, Burrows, GD and Norman, TR. (2004) The treatment of depression with different formulations of venlafaxine: A comparative analysis. Hum Psychopharmacol, 19, pp. 9-16.
36. Cunningham, LA. (1997) Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Ann Clin Psychiatry, 9, pp. 157-164.
37. Bielski, RJ, Ventura, D. and Chang, CC. (2004) A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry, 65, pp. 1190-1196.
38. Sculpher, M. (2001) The role and estimation of productivity cost in economic evaluation. Economic evaluation in health care, pp. 94-112. Oxford University Press, Oxford
39. Wade, AG, Toumi, I. and Hemels, ME. (2005) A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom. Clin Ther, 27, pp. 486-496.
40. Azorin, JM, Llorca, PM, Despiegel, N. and Verpillat, P. (2004) Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder. Encephale, 30, pp. 158-166.
41. Culpepper, L. (2002) Escitalopram: A new SSRI for the treatment of depression in primary care. Prim Care Companion J Clin Psychiatry, 4, pp. 209-214.
42. Moore, N., Verdoux, H. and Fantino, B. (2005) Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol, 20, pp. 131-137.
43. Lieberman, JA, Greenhouse, J., Hamer, RM, Krishnan, KR, Nemeroff, CB and Sheehan, DV (2005) Comparing the effects of antidepressants: Consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology, 30, pp. 445-460.
44. Berk, M. and Dodd, S. (2005) Antidepressants and the placebo response. Hum Psychopharmacol, 20, pp. 305-307.
45. Khan, A. and Brown, WA. (2001) The placebo enigma in antidepressant clinical trials. J Clin Psychopharmacol, 21, pp. 123-125.
46. Hansen, DG, Vach, W., Rosholm, JU, Sondergaard, J., Gram, LF and Kragstrup, J. (2004) Early discontinuation of antidepressants in general practice: Association with patient and prescriber characteristics. Fam Pract, 21, pp. 623-629.
47. Montgomery, SA, Rasmussen, JG and Tanghoj, P. (1993) A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol, 8, pp. 181-188.
48. Robert, P. and Montgomery, SA. (1995) Citalopram in doses of 20-60 mg is effective in depression relapse prevention: A placebo-controlled 6 month study. Int Clin Psychopharmacol, 10, pp. 29-35.
49. Montgomery, SA, Huusom, AK and Bothmer, J. (2004) A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology, 50, pp. 57-64.
50. Demyttenaere, K., Enzlin, P., Dewe, W., Boulanger, B., De, BJ and De, TW (2001) Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events. J Clin Psychiatry, 62, pp. 30-33.
51. Khan, A., Khan, SR, Leventhal, RM and Brown, WA. (2001) Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: A replication analysis of the Food and Drug Administration Database. Int J Neuropsychopharmacol, 4, pp. 113-118.
52. Posternak, MA and Zimmerman, M. (2001) Switching versus augmentation: A prospective, naturalistic comparison in depressed, treatment-resistant patients. J Clin Psychiatry, 62, pp. 135-142.
53. Marangell, LB. (2001) Switching antidepressants for treatment-resistant major depression. J Clin Psychiatry, 62, pp. 12-17.
54. Beasley Jr, CM, Holman, SL and Potvin, JH. (1993) Fluoxetine compared with imipramine in the treatment of inpatient depression. A multicenter trial. Ann Clin Psychiatry, 5, pp. 199-207.
55. Rothschild, AJ, Williamson, DJ, Tohen, MF, Schatzberg, A., Andersen, SW and Van Campen, LE (2004) A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol, 24, pp. 365-373.
56. Bauer, M., Forsthoff, A., Baethge, C., Adli, M., Berghofer, A. and Dopfmer, S. (2002) Lithium augmentation therapy in refractory depression-update 2002. Eur Arch Psychiatry Clin Neurosci, 253, pp. 132-139.